

FireGate Biotech Inc.

News — September 2025

FireGate Update

September 2025 Pipeline & Operations

Pipeline Development

FireGate's research pipeline includes three core initiatives:

- **FG-001 — HIV**
- **FG-002 — Oncology**
- **FG-003 — Neuro-immune repair**

During 2025, development efforts focused primarily on defining program scope, establishing scientific rationale, and conducting early *in silico* feasibility analyses.

Operational Highlights

- Company infrastructure established, including SAM.gov registration and federal eligibility.
- Internal systems prepared to support scientific onboarding and research collaboration.
- Early discussions initiated with academic and industry collaborators.

Execution Roadmap

2025 — Foundation

- Recruit a Director of Operations.
- Engage several qualified scientific Principal Investigators aligned to each core program.

2026 — Funding & Execution

- Submit grant applications to NIH and Department of Defense research programs.
- Establish partnerships with multiple CROs to support preclinical research execution.

About FireGate Biotech Inc.

FireGate Biotech Inc. is a veteran-founded biotechnology company developing modular, triplet-directed research programs across infectious disease, oncology, and neuro-immune biology.

The company's research pipeline includes three programs:

- FG-001 — HIV
- FG-002 — Oncology Viral Mimicry
- FG-003 — Neuro-Immune Repair

Website:

<https://firegatebiotech.com>